Cancer drug shows promise for lupus kidney disease

NCT ID NCT04868838

Ongoing Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This phase 2 trial tests whether daratumumab, a drug used for multiple myeloma, can help people with active lupus nephritis—a serious kidney complication of lupus. The study enrolls adults with confirmed lupus and active kidney inflammation. Participants receive daratumumab injections, and researchers monitor for kidney function improvement and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: daratumumab
What this could lead to: If successful, daratumumab could offer a new treatment option for lupus nephritis, potentially reducing kidney damage and the need for long-term immunosuppression.
What could go wrong: This is a small, early-phase trial with only 12 participants, so results may not apply broadly. Daratumumab can cause infections and other side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUPUS NEPHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lupus nephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUPUS NEPHRITIS

Contacts and locations

Show contact details

Locations

Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.